S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT

• Nausheen Ahmed,
• Swetha Kambhampati,
• Mehdi Hamadani,
• Natalie Grover,
• Mazyar Shadman,
• Frederick Locke,
• James Gerson,
• Matthew J. Frank,
• L. Elizabeth Budde,
• Michael Wang,
• Zhen-Huan Hu,
• Ana Nunes,
• David Dalton,
• Ioana Kloos,
• Daniel Lee,
• Hairong Xu,
• Marcelo Pasquini,
• Alex F. Herrera

Affiliations

Nausheen Ahmed

1 The University of Kansas Medical Center, Westwood, United States

Swetha Kambhampati

2 City of Hope National Medical Center, Duarte, United States

Mehdi Hamadani

3 Center for International Blood and Marrow Transplant Research, Milwaukee, United States

Natalie Grover

4 University of North Carolina, Chapel Hill, United States

Mazyar Shadman

5 Fred Hutchinson Cancer Center, Seattle, United States

Frederick Locke

6 Moffitt Cancer Center, Tampa, United States

James Gerson

7 University of Vermont Medical Center, Burlington, United States

Matthew J. Frank

8 Stanford University, Stanford, United States

L. Elizabeth Budde

2 City of Hope National Medical Center, Duarte, United States

Michael Wang

9 University of Texas MD Anderson Cancer Center, Houston, United States

Zhen-Huan Hu

10 Kite, a Gilead Company, Santa Monica, United States

Ana Nunes

10 Kite, a Gilead Company, Santa Monica, United States

David Dalton

10 Kite, a Gilead Company, Santa Monica, United States

Ioana Kloos

10 Kite, a Gilead Company, Santa Monica, United States

Daniel Lee

10 Kite, a Gilead Company, Santa Monica, United States

Hairong Xu

10 Kite, a Gilead Company, Santa Monica, United States

Marcelo Pasquini

3 Center for International Blood and Marrow Transplant Research, Milwaukee, United States

Alex F. Herrera

2 City of Hope National Medical Center, Duarte, United States